Clinicopathological significance of loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in China

Table 1 Characteristics of microsatellite markers analyzed and patterns of microsatellite alteration in HCC.

Locus	Location	Allelic size(bp)	Heterozygosity (%)	Informative cases	LOH n(%)	MSI n(%)
D1S243	1p36.3	142–170	0.86	35	16(45.7)	3(8.57)
D1S468	1p36.3	173–191	0.75	35	13(37.1)	3(8.57)
D1S2893	1p36.2	201–223	0.47	44	18(40.9)	2(4.55)
D1S2694	1p36.2	241–255	0.65	38	16(42.1)	1(2.63)
D1S450	1p36.2	243–267	0.81	38	17(44.7)	1(2.63)
D1S434	1p36.2	240–252	0.61	42	15(35.7)	0
RIZ	1p36.2	–	–	30	23(76.7)	0
D1S507	1p36.1	183–203	0.78	45	24(53.3)	2(4.44)
D1S199	1p36.1	94–116	0.84	39	14(35.9)	1(2.56)
D1S234	1p36.1	268–294	0.5	37	14(37.8)	3(8.11)
D4S1538	4q22	149–161	0.69	41	17(41.5)	0
D4S1534	4q22	146–158	0.77	41	22(53.7)	0
D4S406	4q26	234–258	0.87	42	22(52.4)	1(2.38)
D4S1625	4q27-31	182–210	0.74	38	13(34.2)	1(2.63)
D4S1652	4q31.1	115–125	0.75	38	16 (42.1)	0
D4S1615	4q34-qter	138–150	0.71	39	19(48.7)	0
D4S2361	4q	149–164	0.7	42	15(35.7)	1(2.38)
D4S1554	4q35	184–208	0.86	37	14(37.8)	0
D4S426	4q35	177–191	0.78	41	25(61)	0
D4S2921	4q35	141–163	0.56	44	23(52.3)	2(4.55)
D8S264	8p23	121–145	0.83	43	19(44.2)	1(2.32)
D8S277	8p23	148–180	0.73	38	18(47.4)	1(2.63)
D8S1706	8p23	257–281	0.88	41	20(48.9)	1(2.43)
D8S1721	8p23	170–212	0.71	40	21(52.5)	0
D8S520	8p23	179–199	0.77	40	20(50.0)	2(5.00)
D8S549	8p22	166–172	0.61	44	20(45.5)	2(4.55)
D8S261	8p22	128–144	0.79	43	23(53.5)	1(2.33)
D8S298	8p22	155–167	0.68	44	23(52.3)	1(2.27)
D8S1733	8p21	253–257	0.64	38	17(44.7)	1(2.63)
D8S1771	8p21	218–240	0.77	40	21(52.5)	1(2.50)
D16S408	16q13	–	–	41	17(41.5)	1(2.22)
D16S512	16q22.1	201–211	0.77	45	20(44.4)	6(13.3)
D16S515	16q22.1	222–244	0.81	36	12(33.3)	2(5.56)
D16S507	16q24.1	175–195	0.78	44	20(45.5)	4(9.09)
D16S534	16q24.2	296–364	0.87	42	21(50.0)	5(11.9)
D16S3091	16q24.2	115–129	0.72	42	22(59.5)	2(4.76)
D16S422	16q24.2	188–212	0.79	42	23(54.8)	2(4.76)
D16S520	16q24.3	181–197	0.84	44	19(43.2)	2(4.55)
D16S413	16q24.2	208–246	0.68	36	16(44.4)	2(5.56)
D16S498	16q24.3	131–149	0.84	46	23(50.0)	1(2.17)
D17S849	17p13.3	251–261	0.69	39	21(53.9)	1(2.56)
D17S926	17p13.3	243–259	0.81	36	21(58.3)	1(2.78)
D17S831	17p13.3	224–246	0.81	37	25(67.6)	3(8.11)
D17S938	17p13.1-p13.3	164–182	0.76	42	21(50.0)	0
D17S786	17p13.1	–	–	39	15(38.5)	1(2.56)
D17S520	17p13.1	135–157	0.77	40	15(37.5)	2(5.00)
D17S799	17p13-p12	–	0.8	42	21(50.0)	2(4.76)
D17S921	17p12	186–200	0.7	39	15(38.5)	0
D17S261	17p11.2	169–185	0.72	41	15(36.6)	1(2.44)
TP53	17p11.2	157–171	0.54	7	4(57.1)	0
D2S123	hMSH-2	197–227		36	3	7(19.4)
BAT-26		116		37	2	9(24.3)
D5S346	APC	96–122		41	1	8(19.5)
D13S170	Rb	220–240		32	4	7(21.9)
D17S250		151–169		33	3	5(15.2)

Table 2 Clinicopathologic correlation of LOH in HCC.

Parameter	Locus	LOH/informative cases		P
HBsAg		Positive	Negative
	D1S2893	17/31	1/13	0.004
	D1S507	13/21	1/16	0.001
	D4S406	20/26	2/16	0.001
	D8S277	16/22	2/16	0.001
	D8S261	10/27	13/16	0.005
	D8S298	11/29	12/15	0.008
	D8S1733	7/24	10/14	0.011
	D16S512	10/31	10/14	0.014
	D16S515	5/27	7/9	0.001
	D17S831	19/21	6/16	0.001
	D17S938	19/25	2/14	0.001
	D17S926	13/27	8/9	0.032
AFP (mg/L)		<20	≥20
	D1S507	3/17	21/29	0.001
	D16S413	9/12	7/24	0.009
Liver cirrhosis		Present	Absent
	D16S534	20/34	1/9	0.011
	D16S3091	24/33	1/9	0.001
	D16S422	22/34	1/8	0.008
	D17S849	21/31	1/8	0.005
	D17S831	24/39	1/8	0.011
	D17S799	20/35	1/7	0.038
Tumor size		≤3 cm	>3 cm
	D8S298	2/9	21/35	0.043
	D8S1771	0/9	21/31	0.001
	D16S498	4/12	19/24	0.007
	D17S926	3/11	18/25	0.012
Histological grade		Well	Moderate and poor
	D4S426	2/11	23/30	0.002
	D4S1615	2/12	14/26	0.04
	D4S1652	2/11	17/28	0.031
	D16S498	2/18	21/29	0.001
	D17S926	4/13	17/23	0.012
Tumor capsule		Absent or not intact	Intact
	D8S1721	20/28	1/12	0.001
Intrahepatic metastasis		Not observed	Observed
	D1S468	8/10	5/25	0.001
	D4S2921	2/21	21/23	0.023
	D8S298	2/10	21/34	0.02
	D8S1771	2/9	19/31	0.039
	D17S926	1/11	20/25	0.001
	D17S786	0/10	15/29	0.004